3928 Point Eden Way
About Arcus Biosciences
Arcus was founded in 2015 by Terry Rosen and Juan Jaen to discover and develop innovative cancer immunotherapies based on known but under exploited biology. Prior to starting Arcus, Terry and Juan founded Flexus Biosciences, which in February 2015 sold its preclinical-stage IDO inhibitor to Bristol-Myers Squibb for $800M upfront and $450M in milestones. The inhibition of IDO is now viewed as one of the most promising immuno-oncology mechanisms in late-stage development. We believe there is a significant opportunity to develop novel drugs that target other prevalent mechanisms of tumor-induced immuno-suppression or that act through the selective activation of effector immune mechanisms.
Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the translation of unexploited insights in immunology. The company was recently formed by a group of seasoned researchers from the biotechnology and pharmaceutical industries.
Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment. Like IDO inhibitors, adenosine receptor antagonists and inhibitors of adenosine production are expected to be highly synergistic with other immuno-oncology mechanisms, as well as with chemotherapy. Because of the promise of the adenosine pathway, several adenosine receptor antagonists that were discovered years ago and initially developed for other indications have been repurposed for oncology. Using our expertise in medicinal chemistry and drug discovery, we have generated novel, small- molecule dual antagonists of key adenosine receptors A2aR and A2bR. We believe that our lead molecule, AB928, will be the first clinical compound that was designed specifically for its immune-stimulating properties. AB928, like the IDO inhibitor we discovered at Flexus, has the potential to be best-in-class and we expect to advance this compound into clinical trials later this year. We have other product candidates in earlier stages of development that target the adenosine pathway, including a CD73 inhibitor (which blocks the generation of extracellular adenosine in tumors) that could be the first small-molecule inhibitor of CD73 to enter clinical trials.
We also have several small-molecule programs in earlier stages of discovery targeting other key pathways in immuno-oncology. In addition to our small- molecule programs, we are advancing several antibody programs against other targets. We expect to initiate clinical trials in 2018 for AB154, our lead antibody product candidate which targets TIGIT. An important element of our strategy is the development of intra-portfolio combinations of our small- molecule and antibody product candidates, and we believe that many of these combinations will be the first to advance into clinical trials.
Co-Founder and CEO: Terry Rosen, Ph.D.
Co-Founder and President: Juan Jaen, Ph.D.
VP, Biology: Ulrike Schindler, Ph.D.
VP, Drug Discovery: Jay Powers, Ph.D.
VP, Technology: Steve Young, Ph.D.
VP, Protein Science: Nigel Walker, Ph.D.
Please click here for Arcus Biosciences job opportunities.
Please click here for Arcus Biosciences' pipeline.
16 articles with Arcus Biosciences
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
Ms. Jarrett will be responsible for several key areas, including finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources.
Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations
Phase 1/1b trial to evaluate the safety, tolerability and preliminary efficacy in patients with breast and gynecologic malignancies.
CEO "extremely encouraged by the results from our ongoing Phase 1 trial of AB928."
Arcus Biosciences announced that five abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, Illinois.
Arcus Biosciences announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15.00 per share for total gross proceeds of $120,000,000.
Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization.
11/27/2017Sage Therapeutics has been on a roll with good news lately.
Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing.